BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 27392615)

  • 1. Malignant lipogenesis defined by
    Regula N; Häggman M; Johansson S; Sörensen J
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2131-2138. PubMed ID: 27392615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
    Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
    J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [(11) C]acetate PET as a prognostic marker.
    Leisser A; Pruscha K; Ubl P; Wadsak W; Mayerhöfer M; Mitterhauser M; Hacker M; Kramer G; Shariat S; Karanikas G; Hartenbach M; Haug AR
    Prostate; 2015 Nov; 75(15):1760-7. PubMed ID: 26282590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy.
    Giovacchini G; Picchio M; Garcia-Parra R; Briganti A; Abdollah F; Gianolli L; Schindler C; Montorsi F; Messa C; Fazio F
    J Nucl Med; 2014 Feb; 55(2):233-41. PubMed ID: 24408897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.
    Oyama N; Miller TR; Dehdashti F; Siegel BA; Fischer KC; Michalski JM; Kibel AS; Andriole GL; Picus J; Welch MJ
    J Nucl Med; 2003 Apr; 44(4):549-55. PubMed ID: 12679398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients.
    Fricke E; Machtens S; Hofmann M; van den Hoff J; Bergh S; Brunkhorst T; Meyer GJ; Karstens JH; Knapp WH; Boerner AR
    Eur J Nucl Med Mol Imaging; 2003 Apr; 30(4):607-11. PubMed ID: 12589476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 11C-acetate positron-emission tomography/computed tomography imaging for detection of recurrent disease after radical prostatectomy or radiotherapy in patients with prostate cancer.
    Esch LH; Fahlbusch M; Albers P; Hautzel H; Müller-Mattheis V
    BJU Int; 2017 Sep; 120(3):337-342. PubMed ID: 27860163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [¹¹C]Choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy.
    Giovacchini G; Incerti E; Mapelli P; Kirienko M; Briganti A; Gandaglia G; Montorsi F; Gianolli L; Picchio M
    Eur J Nucl Med Mol Imaging; 2015 May; 42(6):877-84. PubMed ID: 25697127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
    Castellucci P; Ceci F; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Pettinato C; Celli M; Lodi F; Fanti S
    J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [11C]Acetate positron emission tomography-computed tomography imaging of prostate cancer lymph-node metastases correlated with histopathological findings after extended lymphadenectomy.
    Schumacher MC; Radecka E; Hellström M; Jacobsson H; Sundin A
    Scand J Urol; 2015 Feb; 49(1):35-42. PubMed ID: 25001948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy.
    Vees H; Buchegger F; Albrecht S; Khan H; Husarik D; Zaidi H; Soloviev D; Hany TF; Miralbell R
    BJU Int; 2007 Jun; 99(6):1415-20. PubMed ID: 17428249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.
    Graziani T; Ceci F; Castellucci P; Polverari G; Lima GM; Lodi F; Morganti AG; Ardizzoni A; Schiavina R; Fanti S
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1971-9. PubMed ID: 27277279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation Treatment of Lymph Node Recurrence from Prostate Cancer: Is 11C-Choline PET/CT Predictive of Survival Outcomes?
    Incerti E; Fodor A; Mapelli P; Fiorino C; Alongi P; Kirienko M; Giovacchini G; Busnardo E; Gianolli L; Di Muzio N; Picchio M
    J Nucl Med; 2015 Dec; 56(12):1836-42. PubMed ID: 26405166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer.
    Kotzerke J; Volkmer BG; Neumaier B; Gschwend JE; Hautmann RE; Reske SN
    Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1380-4. PubMed ID: 12271422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
    Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
    Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Giovacchini G; Guglielmo P; Mapelli P; Incerti E; Gajate AMS; Giovannini E; Riondato M; Briganti A; Gianolli L; Ciarmiello A; Picchio M
    Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):921-929. PubMed ID: 30631911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased Prostate Cancer Glucose Metabolism Detected by
    Lavallée E; Bergeron M; Buteau FA; Blouin AC; Duchesnay N; Dujardin T; Tiguert R; Lacombe L; Fradet V; Makao-Nguile M; Fradet Y; Beauregard JM; Pouliot F
    Eur Urol Focus; 2019 Nov; 5(6):998-1006. PubMed ID: 29609897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy.
    Giovacchini G; Picchio M; Parra RG; Briganti A; Gianolli L; Montorsi F; Messa C
    Clin Nucl Med; 2012 Apr; 37(4):325-31. PubMed ID: 22391699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.